Enzyme replacement therapy (ERT) is a medical treatment that supplies a working version of an enzyme your body can’t produce on its own. It’s the primary treatment for a group of rare inherited conditions called lysosomal storage diseases, where a missing or defective enzyme causes harmful substances to build up inside cells. The first ERT was approved by the FDA in 1991 for Type 1 Gaucher disease, and today there are FDA-approved therapies for at least eight different conditions.
How ERT Works Inside Your Cells
Every cell in your body contains tiny compartments called lysosomes, which act like recycling centers. Lysosomes use specialized enzymes to break down waste products, fats, sugars, and proteins. When one of these enzymes is missing or broken due to a genetic mutation, waste accumulates in the lysosomes and eventually damages tissues and organs.
ERT delivers a lab-made copy of the missing enzyme directly into your bloodstream through an IV. These replacement enzymes are tagged with a molecular marker called mannose-6-phosphate, which acts like an address label. Cells throughout your body have receptors on their surface that recognize this tag, pull the enzyme inside, and shuttle it into the lysosomes where it’s needed. Once there, the acidic environment inside the lysosome (around pH 5) activates the enzyme so it can start clearing the built-up waste. Over time, this reduces the toxic accumulation that causes organ damage, bone disease, and other symptoms.
Conditions Treated With ERT
All conditions treated by ERT fall under the umbrella of lysosomal storage diseases. Each involves a different missing enzyme and affects the body in different ways:
- Type 1 Gaucher disease: A fatty substance called glucocerebroside builds up in the spleen, liver, and bone marrow, causing enlarged organs, anemia, low platelet counts, and bone problems. Three separate ERT products are approved for this condition.
- Fabry disease: Fatty deposits accumulate in blood vessel walls and organs, leading to pain, kidney damage, heart problems, and stroke risk.
- Pompe disease: Glycogen (a stored sugar) builds up in muscles, causing progressive weakness. One form of ERT is approved for infantile-onset Pompe disease, and another specifically for late-onset cases in patients 8 and older without heart enlargement.
- MPS I (Hurler, Hurler-Scheie, and Scheie syndromes): Complex sugars called glycosaminoglycans accumulate throughout the body, affecting joints, bones, the heart, and airways.
- MPS II (Hunter syndrome): Similar sugar buildup to MPS I, primarily affecting males.
- MPS VI (Maroteaux-Lamy syndrome): Another glycosaminoglycan storage disorder causing skeletal abnormalities and organ enlargement.
What an Infusion Looks Like
ERT is given as an intravenous infusion, typically every one to two weeks, depending on the condition. Some therapies require weekly sessions. Each infusion takes anywhere from one to four hours. For Gaucher disease, treatments usually run one to two hours. For Pompe disease, infusions take closer to four hours because of the larger volume of fluid involved. Most patients receive their infusions at a hospital or infusion center, though some eventually transition to home infusions once their tolerance is established.
Because ERT is a lifelong treatment, the time commitment is significant. A patient with Fabry disease, for example, will spend at least 1.5 hours every two weeks receiving their infusion, plus travel and monitoring time, for the rest of their life.
Side Effects and Immune Reactions
The most common side effects are infusion-associated reactions. These range from mild symptoms like skin rash, itching, flushing, and cough to more serious responses including throat tightness, shortness of breath, low blood pressure, and in rare cases, full anaphylaxis. Reactions can occur even on the first exposure to the enzyme. To reduce these risks, many patients are given pre-medications before each infusion, including antihistamines, corticosteroids, or fever reducers.
A more complex problem is that the immune system can recognize the replacement enzyme as foreign and produce antibodies against it. In Fabry disease, this is a particular concern for male patients with the classic form of the disease. One study found that 28% of patients on one formulation and 52% on another developed these anti-drug antibodies. When neutralizing antibodies form, they can bind to the replacement enzyme and reduce its effectiveness, potentially undermining the entire treatment. Managing this immune response is one of the ongoing challenges of ERT.
What ERT Can and Can’t Do
ERT is effective at reducing organ enlargement, improving blood counts, and slowing the progression of damage in tissues that the enzyme can reach through the bloodstream. For Gaucher disease, treatment can significantly shrink an enlarged spleen and liver, improve anemia, and reduce bone complications. For Pompe disease, it can stabilize or improve muscle function, particularly when started early.
The major limitation is the brain. More than 70% of all patients with lysosomal storage diseases have some degree of neurological involvement, yet ERT largely cannot address it. The blood-brain barrier, a tightly sealed layer of cells lining the brain’s blood vessels, blocks the large enzyme molecules from crossing into brain tissue. This is especially relevant for severe forms of MPS I, MPS II, MPS III (all forms), and MPS VII, where progressive cognitive decline is a defining feature of the disease. MPS IV and MPS VI, by contrast, typically don’t involve significant brain damage, making ERT more comprehensively effective for those conditions.
Newer Approaches to Improve ERT
Several strategies are being developed to overcome ERT’s current shortcomings. One approach involves engineering replacement enzymes with a much higher concentration of the mannose-6-phosphate tag, improving how efficiently cells absorb them. A next-generation Pompe disease therapy, for instance, was designed with a 15-fold increase in this molecular tag compared to the original version, boosting cellular uptake significantly. Since most ERTs rely on this same uptake pathway, the technique could potentially improve treatments across multiple diseases.
Another focus is reducing immune reactions. Attaching a polymer shield to the enzyme (a process called PEGylation) can help the enzyme evade the immune system and stay in the bloodstream longer before being cleared. However, some patients develop immunity to the shield itself, so researchers are exploring alternatives. Fusing the enzyme with a fragment of a human antibody is one such option, which can extend how long the enzyme circulates in the body without triggering as strong an immune response.